Figure 7

SSR240612 reduced microglial, but not astroglial, activation in the APP mouse brain. (A) As observed with glial fibrillary acidic protein (GFAP) immunolabeling (left), 5 and 10 weeks of treatment did not reduce astrocytosis in APP mice. (B) Following immunolabeling of microglial marker Iba1, SSR240612 treatments (10 weeks, left, compared to vehicle-treated mice) significantly reduced microglial activation (percentage of positive area) and aggregation (maximal labeling intensity). High magnifications are shown in insets in A and B. After 5 weeks of treatment, the effects were barely significant in hippocampus including the dentate gyrus (DG). Scale bars: 300 μm. Error bars represent SEM. *, †P <0.05; **, ††P <0.01; ***, †††P <0.001 (†: vs. WT; *: non-treated APP vs. treated APP). Two-way ANOVA followed by Newman-Keuls post hoc test. N = 5 to 6/group. APP, amyloid precursor protein; Iba1, ionized calcium-binding adaptor molecule 1; WT, wild-type.